Abstract
Modeling the flow and level of prostaglandins in open systems under the action of prostaglandin H synthase (PGHS) inhibitors (nonsteroidal anti-inflammatory drugs, NSAIDs) was carried out. These open systems included a steady PGHS input, fast inactivation of PGHS during the reaction, degradation of all PGHS forms, conversion of prostaglandin (PG) to biologically inactive substances, and various types of delivery of inhibitors and substrate (arachidonic acid, AA). A slow reversible inhibitor of PGHS (indomethacin) and a slow irreversible inhibitor of PGHS (aspirin) were considered as inhibitors. The explicit analytical expressions for flows and concentrations in steady state and transient mode were obtained. In steady state the dependences of flow and level of PG on the concentration of AA were described by the Michaelis–Menten-type equation. The values of the maximum flows, maximum levels, and Michaelis constant in these equations are inversely proportional to the constant of inactivation of the enzyme during the reaction. In the closed systems, slow PGHS inhibitors are manifested as non-competitive with respect to AA, but in open systems, their behavior is fully competitive with respect to AA, so the presence of inhibitor increases the range of changes of PG level under the change of AA concentration. The reversible inhibitor (indomethacin), in contrast to the irreversible inhibitor (aspirin), in transient mode has been shown to manifest itself as the repository for the active enzyme because of the formation of enzyme-inhibitory complexes. The system disturbance under the rapid increase of indomethacin concentration leads to the biphasic change of the PG level: after the initial rapid decrease it increases gradually to the new steady state. In the presence of indomethacin, the system disturbance under the rapid increase of AA concentration leads to the release of the enzyme from enzyme-inhibitory complexes, and the PG level for a certain period significantly increases compared with the absence of inhibitor. The results of modeling of the regulation of the level of prostaglandins in different states of the open systems undoubtedly need to be used in the study of NSAIDs in vivo.
Similar content being viewed by others
REFERENCES
Ricciotti, E. and Fitzgerald, G.A., Arterioscler. Thromb. Vasc. Biol., 2011, vol. 31, pp. 986–1000. https://doi.org/10.1161/ATVBAHA.110.207449
Hamberg, M., Svensson, J., Wakabayashi, T., and Samuelsson, B., Proc. Natl. Acad. Sci. U. S. A., 1974, vol. 71, pp. 345–349. https://doi.org/10.1073/pnas.71.2.345
Wu, G., Vuletich, J.L., Kulmacz, R.J., Osawa, Y., and Tsai, A.L., J. Biol. Chem., 2001, vol. 276, pp. 19879–19888. https://doi.org/10.1074/jbc.M100628200
Hamberg, M. and Samuelsson, B., Proc. Natl. Acad. Sci. U. S. A., 1973, vol. 70, pp. 899–903. https://doi.org/10.1073/pnas.70.3.899
Samuelsson, B., Goldyne, M., Granstrom, E., Hamberg, M., Hammarstrom, S., and Malmsten, C., Annu. Rev. Biochem., 1978, vol. 47, pp. 997–1029. https://doi.org/10.1146/annurev.bi.47.070178.005025
Helliwell, R.J., Adams, L.F., and Mitchell, M.D., Prostaglandins Leukot. Essent. Fatty Acids, 2004, vol. 70, pp. 101–113. https://doi.org/10.1016/j.plefa.2003.04.002
Watanabe, K., Yoshida, R., Shimizu, T., and Hayaishi, O., J. Biol. Chem., 1985, vol. 260, pp. 7035–7041.
Vrzheshch, P.V., Batanova, E.A., Mevkh, A.T., Varfolomeev, S.D., Gazaryan, I.G., and Thorneley, R.N., Biochem. J., 2003, vol. 372, pp. 713–724. https://doi.org/10.1042/BJ20030043
Smith, W.L. and Lands, W.E., Biochemistry, 1972, vol. 11, pp. 3276–3285. https://doi.org/10.1021/bi00767a024
Egan, R.W., Paxton, J., and Kuehl, F.A., J. Biol. Chem., 1976, vol. 251, pp. 7329–7335.
Mevkh, A.T., Vrzheshch, P.V., Svedas, V.Y.-K., Varfolomeev, S.D., Myagkova, G.I., and Yakusheva, L.A, Bioorg. Khim., 1981, vol. 7, pp. 695–702.
Vrzheshch, P.V., Tsaplina, L.A., and Sakharova, I.S., Biochemistry (Mosc.), 2007, vol. 72, pp. 828–834. https://doi.org/10.1134/s0006297907080032
Yokoyama, C. and Tanabe, T., Biochem. Biophys. Res. Commun., 1989, vol. 165, pp. 888–894. https://doi.org/10.1016/s0006-291x(89)80049-x
Jones, D.A., Carlton, D.P., McIntyre, T.M., Zimmerman, G.A., and Prescott, S.M., J. Biol. Chem., 1993, vol. 268, pp. 9049–9054.
Vane, J.R., Nat. New Biol., 1971, vol. 231, pp. 232–235. https://doi.org/10.1038/newbio231232a0
Smith, W.L., Meade, E.A., and DeWitt, D.L., Ann. N.Y. Acad. Sci., 1994, vol. 714. https://doi.org/10.1111/j.1749-6632.1994.tb12037.x
Bacchi, S., Palumbo, P., Sponta, A., and Coppolino, M.F., Antiinflamm. Antiallergy Agents Med. Chem., 2012, vol. 11, pp. 52–64. https://doi.org/10.2174/187152312803476255
Gabrielsson, J. and Peletier, L.A., AAPS J., 2018, vol. 20, p. 102. https://doi.org/10.1208/s12248-018-0256-z
Westley, A.M. and Westley, J., J. Biol. Chem., 1996, vol. 271, pp. 5347–5352. https://doi.org/10.1074/jbc.271.10.5347
Liu, W., Poole, E.M., Ulrich, C.M., and Kulmacz, R.J., Pharmacogenet. Genomics, 2012, vol. 22, pp. 525–537. https://doi.org/10.1097/FPC.0b013e32835366f6
Schlosser, M., Walschus, U., Klöting, I., and Walther, R., Dis. Markers, 2008, vol. 24, pp. 191–198. https://doi.org/10.1155/2008/961421
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., and Raunio, H., Arch. Toxicol., 2008, vol. 82, pp. 667–715. https://doi.org/10.1007/s00204-008-0332-8
Mathieson, T., Franken, H., Kosinski, J., Kurzawa, N., Zinn, N., Sweetman, G., Poeckel, D., Ratnu, V.S., Schramm, M., Becher, I., Steidel, M., Noh, K.-M., Bergamini, G., Beck, M., Bantscheff, M., and Savitski, M.M., Nat. Commun., 2018, vol. 9, p. 689. https://doi.org/10.1038/s41467-018-03106-1
Cohen, L.D., Zuchman, R., Sorokina, O., Müller, A., Dieterich, D.C., Armstrong, J.D., Ziv, T., and Ziv, N.E., PLoS One, 2013, vol. 8. e63191. https://doi.org/10.1371/journal.pone.0063191
Fowler, J.S., Volkow, N.D., Logan, J., Wang, G.J., MacGregor, R.R., Schyler, D., Wolf, A.P., Pappas, N., Alexoff, D., and Shea, C., Synapse, 1994, vol. 18, pp. 86–93. https://doi.org/10.1002/syn.890180203
Yang, J., Liao, M., Shou, M., Jamei, M., Yeo, K.R., Tucker, G.T., and Rostami-Hodjegan, A., Curr. Drug Metab., 2008, vol. 9, pp. 384–394. https://doi.org/10.2174/138920008784746382
von Bahr, C., Steiner, E., Koike, Y., and Gabrielsson, J., Clin. Pharmacol. Ther., 1998, vol. 64, pp. 18–26. https://doi.org/10.1016/S0009-9236(98)90018-2
Flower, R.J., Biochem. Soc. Trans., 1978, vol. 6, pp. 713–714. https://doi.org/10.1042/bst0060713a
Brash, A.R., J. Clin. Invest., 2001, vol. 107, pp. 1339–1345. https://doi.org/10.1172/JCI13210
Filimonov, I.S., Berzova, A.P., Barkhatov, V.I., Krivoshey, A.V., Trushkin, N.A., and Vrzheshch, P.V., Biochemistry (Mosc.), 2018, vol. 83, pp. 119–128. https://doi.org/10.1134/S0006297918020049
Pompeia, C., Lima, T., and Curi, R., Cell Biochem. Funct., 2003, vol. 21, pp. 97–104. https://doi.org/10.1002/cbf.1012
Alván, G., Orme, M., Bertilsson, L., Ekstrand, R., and Palmér, L., Clin. Pharmacol. Ther., 1975, vol. 18, pp. 364–373. https://doi.org/10.1002/cpt1975183364
Rosenkranz, B. and Frölich, J.C., Prostaglandins Leukot. Med., 1985, vol. 19, pp. 289–300. https://doi.org/10.1016/0262-1746(85)90142-8
Murakami, M., Nakatani, Y., Atsumi, G.-I., Inoue, K., and Kudo, I., Crit. Rev. Immunol., 2017, vol. 37, pp. 127–195. https://doi.org/10.1615/CritRevImmunol.v37.i2-6.20
Ponomareva, O.A., Trushkin, N.A., Filimonov, I.S., Krivoshey, A.V., Barkhatov, V.I., Mitrofanov, S.I., and Vrzheshch, P.V., Biochim. Biophys. Acta, 2016, vol. 1858, pp. 2199–2207. https://doi.org/10.1016/j.bbamem.2016.06.013
Stoscheck, C.M., Methods Enzymol., 1990, vol. 182, pp. 50–68. https://doi.org/10.1016/0076-6879(90)82008-p
Falk, J.E., Porphyrins and Metalloporphyrins. Their General, Physical and Coordination Chemistry, and Laboratory Methods, Amsterdam–London–New York: Elsevier Publ. Comp., 1964, p. 181. https://doi.org/10.1002/jobm.19640040512
ACKNOWLEDGMENTS
The study was carried out using the equipment purchased at the expense of the Development Program of Moscow State University and equipment of the Center for Collective Use of Ultra-High Performance Computing Resources of Lomonosov Moscow State University.
Funding
The work was supported by the Russian Foundation for Basic Research (project no. 19-04-01150а).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
COMPLIANCE WITH ETHICAL STANDARDS
The article contains no studies involving animals or humans as subjects of the study.
Conflict of Interests
Authors declare they have no conflicts of interests.
Additional information
Translated by N. Onishchenko
Abbreviations: NSAID, nonsteroidal anti-inflammatory drugs; AA, arachidonic acid; COX, cyclooxygenase; DEDTC, sodium diethyldithiocarbamate; PG, prostaglandin; PGHS, prostaglandin H synthase.
Corresponding author: phone: +7 (967) 005-07-54.
Supplementary Information
Rights and permissions
About this article
Cite this article
Krivoshey, A.V., Efremov, A.A., Matveishina, E.K. et al. Simulation of the Level of Prostaglandins in Open Systems under the Action of Nonsteroidal Anti-Inflammatory Drugs. Russ J Bioorg Chem 47, 1051–1059 (2021). https://doi.org/10.1134/S1068162021050289
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1068162021050289